ArticleBiologics : targets & therapy2007
The molecular genetics of breast cancer and targeted therapy.
Article in Biologics : targets & therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Targeting the Key Signaling Pathways in Breast Cancer: From Molecular Mechanism to Therapeutic Interventions.Recent patents on anti-cancer drug discovery · 2025Review
- Controversial Role of Opioids: From Pain Control to Cancer Recurrence in Breast Cancer.Current cancer drug targets · 2025Review
- Understanding genetic variations associated with familial breast cancer.World journal of surgical oncology · 2024Review
- Overexpression of WT1 in all molecular subtypes of breast cancer and its impact on survival: exploring oncogenic and tumor suppressor roles of distinct WT1 isoforms.Molecular biology reports · 2024Article
- Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Signaling pathways governing breast cancer stem cells behavior.Stem cell research & therapy · 2021Review
- Long Non-Coding RNAs as Potential Diagnostic and Prognostic Biomarkers in Breast Cancer: Progress and Prospects.Frontiers in oncology · 2021Review
- Ethanolic Extracts fromInternational journal of molecular sciences · 2018Article
- The toxicity and therapeutic effects of single-and multi-wall carbon nanotubes on mice breast cancer.Scientific reports · 2018Article
- Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer.International journal of molecular sciences · 2017Review
- Reduced changes in protein compared to mRNA levels across non-proliferating tissues.BMC genomics · 2017Article
- What is known about melatonin, chemotherapy and altered gene expression in breast cancer.Oncology letters · 2017Article
- An integrative transcriptomics approach identifies miR-503 as a candidate master regulator of the estrogen response in MCF-7 breast cancer cells.RNA (New York, N.Y.) · 2016Article
- TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer.Oncotarget · 2015Article
- Estrogen Regulates MAPK-Related Genes through Genomic and Nongenomic Interactions between IGF-I Receptor Tyrosine Kinase and Estrogen Receptor-Alpha Signaling Pathways in Human Uterine Leiomyoma Cells.Journal of signal transduction · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a complex, molecular disease, in which a number of cellular pathways involving cell growth and proliferation, such as the MAPK, RB/E2F, P13K/AKT/mTOR, and TP53 pathways, are altered. These pathways represent molecular mechanisms that are composed and regulated by various genes. The genes that are altered in terms of cell growth and proliferation include the oncogenes HER2, c-MYC, and RAS, the ER genes, and the genes for cell cyclin D1 and E, and the tumor suppressor genes RB, TP53, and PTEN, and the breast cancer susceptibility genes BRCA1 and BRCA2. Although the nature of breast cancer is complex and has frustrated previous attempts at treatment or prevention, the elucidation of its molecular nature over the last several decades is now providing targets for effective therapies to treat the disease and hopefully one day to prevent it.
Indexed as
Identifiers
19707334PMC2721311W2344865495What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.